Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study

Abstract

Currently available monotherapies of oral nucleoside/nucleotide analogs or interferon are unable to achieve a sustained and effective response in most of patients with chronic hepatitis B (CHB). The objective of the present study was to compare the efficacy and safety of pegylated interferon (Peg-IFN) alpha-2b plus adefovir dipivoxil combination therapy versus Peg-IFN alpha-2b alone. Sixty-one HBeAg-positive chronic hepatitis B patients were randomized to receive Peg-IFN alpha-2b alone (1.5 μg/kg once weekly) or Peg-IFN alpha-2b plus adefovir (10 mg daily) for up to 52 weeks. Efficacy and safety analyses were performed on all participants who received at least one dose of study medication. The rate of HBeAg seroconversion and undetectable HBV-DNA were evaluated after 52 weeks of therapy. At the end of treatment, 11 of 30 (36.7%) patients receiving combination therapy achieved HBeAg seroconversion versus 8 of 31 (25.8%) in the monotherapy group (P=0.36). In contrast, the percentage of patients with undetectable serum HBV DNA was significantly higher in the combination group than in the monotherapy group (76.7% vs. 29.0%, P<0.001). Thyroid dysfunction was more frequent in the combination group than in the monotherapy group (P<0.05). In HBeAg-positive CHB, combination of Peg-IFN alpha-2b and adefovir for 52 weeks resulted, at the end of treatment, in a higher virological response but without significant impact on the rate of HBeAg seroconversion and possibly an adverse effect on thyroid function.

Keywords

chronic hepatitis B / therapy / pegylated interferon alpha-2b / adefovir dipivoxil

References

[1] LokAS, McMahonBJ. Chronic hepatitis B. Hepatology, 2007, 45(2): 507-539

[2] CuiY, JiaJ. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol, 2013, 28(Suppl1): 7-10

[3] . J Hepatol, 2012, 57(1)

[4] LiawYF, KaoJH, PiratvisuthT, et al.. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int, 2012, 6(3): 531-561

[5] KimSS, CheongJY, ChoSW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. Gut Liver, 2011, 5(3): 278-287

[6] LeungN. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int, 2008, 2(2): 163-178

[7] LiWC, WangMR, KongLB, et al.. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis, 2011, 11: 165

[8] ZhaoP, LiuW, ZhaoJ, et al.. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naive Asian patients with chronic hepatitis B: a meta-analysis. Virol J, 2011, 8: 75

[9] WursthornK, LutgehetmannM, DandriM, et al.. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 2006, 44(3): 675-684

[10] FungJ, LaiCL, SetoWK, et al.. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother, 2011, 66(12): 2715-2725

[11] SarinSK, SoodA, KumarM, et al.. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol, 2007, 102(1): 96-104

[12] PiccoloP, LenciI, di PaoloD, et al.. A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther, 2013, 18(1): 57-64

[13] . Zhonghua Gan Zang Bing Za Zhi (Chinese), 2011, 19(1)

[14] JinR, GuoXH, HuangJF, et al.. A multicenter study of the effectiveness of interferon alpha-1b (Hapgen) in treating HBeAg positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi (Chinese), 2011, 19(1): 25-28

[15] PiccoloP, LenciI, DemeliaL, et al.. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis Be antigen-negative chronic hepatitis B. Antivir Ther, 2009, 14(8): 1165-1174

[16] LauGK, PiratvisuthT, LuoKX, et al.. Peginterferon Alfa-2a, lamivudine, and the combination for HBe-Ag-positive chronic hepatitis B. N Engl J Med, 2005, 352(26): 2682-2695

[17] HuangR, HaoY, ZhangJ, et al.. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res, 2013, 43(10): 1040-1051

[18] TsiangM, RooneyJF, TooleJJ, et al.. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology, 1999, 29(6): 1863-1869